Revenue from operations grew by 5.27% year on year to Rs 953.38 crore in the quarter ended 30 September 2023.

Profit before tax stood at Rs 296.51 crore in Q2 FY24, up 13.03% as against Rs 262.33 crore recorded in the corresponding quarter previous year.

The pharma company’s EBITDA margin stood at 25.3% during the quarter.

On half-yearly basis, the firm’s net profit increased 11.94% to Rs 346.12 crore on 3.45% rise in revenue to Rs 1691.40 crore in H1 FY24 over H1 FY23.

Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, "Our Q2 performance reflects an overall recovery with market share gains in several key promoted brands across all business units. We held leadership position for our key brands in relevant therapy areas such as anti-infectives and dermatology.

Our focus in the coming quarters will remain on strong volume led performance in General Medicines and Paediatric vaccines. We will also explore innovative solutions using Omnichannel strategy to expand our reach and coverage to our target segments. We continue to drive the expansion of the adult immunisation category with Shingrix (Zoster Vaccine Recombinant, Adjuvanted).”

GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.